EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

ERK1/2 Inhibition Alleviates Diabetic Cardiomyopathy by Suppressing Fatty Acid Metabolism

Erin McLean, Caroline De Roo, Annabel Maag, Megan Coble, Jefferson Cano, Ruijie Liu

Frontiers in Bioscience-Landmark · 22.01.2025 · 30 (1)

DOI: 10.31083/fbl26700 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Bioscience-Landmark, online erschienen am 22.01.2025. Verfasst von Erin McLean und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedical Sciences, Grand Valley State University, Allendale, MI 49401, USA. Hauptthemen laut MEDLINE: Diabetic Cardiomyopathies, Fatty Acids, Diabetes Mellitus, Experimental, Mitogen-Activated Protein Kinase 3. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 77 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Center for Scholarly and Creative Excellence, Department of Biomedical Sciences at the Grand Valley State University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Diabetes mellitus is associated with morphological and functional impairment of the heart primarily due to lipid toxicity caused by increased fatty acid metabolism. Extracellular signal-regulated protein kinases 1 and 2 (ERK1/2) have been implicated in the metabolism of fatty acids in the liver and skeletal muscles. However, their role in the heart in diabetes remains unclear. In this study, we tested our hypothesis that pharmacological inhibition of ERK1/2 alleviates cardiac remodeling in diabetic mice through a reduction in fatty acid metabolism.

Methods

ERK1/2 phosphorylation in diabetes was determined both in vitro and in vivo. H9C2 cells were subjected to high glucose, high palmitic acid, or both high glucose and palmitic acid. db/db and streptozotocin (STZ)-induced diabetic mice were analyzed for ERK1/2 phosphorylation levels as well as the effects of U0126 treatment on cardiac remodeling. Administration of STZ and U0126 in mice was performed via intraperitoneal injection. Blood glucose levels in mice were measured using a glucometer. Mouse heart total RNAs were purified for reverse transcription. Real-time polymerase chain reaction (PCR) analysis of the messenger ribonucleic acid (mRNA) expression was performed for hypertrophy (ANF, BNP, and βMHC), fibrosis (Col3α1), and fatty acid metabolism genes (PPARα, CPT1A, and FACS). Interstitial fibrosis of the myocardium was analyzed using Masson’s trichrome staining of the paraffin-embedded tissues.

Results

ERK1/2 phosphorylation was significantly increased in diabetic conditions. Inhibition of ERK1/2 by U0126 in both streptozotocin-induced diabetic mice and db/db mice resulted in a significant reduction in the expression of genes associated with hypertrophy and fibrosis. In contrast, elevated phosphorylation of ERK1/2 in Dusp6/8 knockout (DKO) mice resulted in fibrosis. Mechanistically, ERK1/2 activation enhanced the expression of fatty acid metabolism genes PPARα, CPT1A, and FACS in the heart, which was reversed by U0126 treatment.

Conclusion

ERK1/2 are potential therapeutic targets for diabetic cardiomyopathy by modulating fatty acid metabolism in the heart.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetic CardiomyopathiesFatty AcidsDiabetes Mellitus, ExperimentalMitogen-Activated Protein Kinase 3MAP Kinase Signaling SystemMitogen-Activated Protein Kinase 1AnimalsMiceMaleButadienesPhosphorylationNitrilesCell LineRatsMice, Inbred C57BLMyocardium

Stichwörter der Autor:innen

ERK1/2cardiac remodelingdiabetes mellitusfatty acid metabolism

Substanzen

Fatty AcidsU 0126ButadienesMitogen-Activated Protein Kinase 3NitrilesMitogen-Activated Protein Kinase 1

Autor:innen und Institutionen

  • Department of Biomedical Sciences, Grand Valley State University, Allendale, MI 49401, USA.

Förderung

  • Center for Scholarly and Creative Excellence
  • Department of Biomedical Sciences at the Grand Valley State University

Zitieren

APA

McLean, E., Roo, C., Maag, A., Coble, M., Cano, J., & Liu, R. (2025). ERK1/2 Inhibition Alleviates Diabetic Cardiomyopathy by Suppressing Fatty Acid Metabolism. Frontiers in Bioscience-Landmark, 30(1). https://doi.org/10.31083/fbl26700

Vancouver

McLean E, Roo C, Maag A, Coble M, Cano J, Liu R. ERK1/2 Inhibition Alleviates Diabetic Cardiomyopathy by Suppressing Fatty Acid Metabolism. Frontiers in Bioscience-Landmark. 2025;30(1). doi:10.31083/fbl26700

BibTeX
@article{McLean2025,
  author = {McLean, Erin and Roo, Caroline De and Maag, Annabel and Coble, Megan and Cano, Jefferson and Liu, Ruijie},
  title = {ERK1/2 Inhibition Alleviates Diabetic Cardiomyopathy by Suppressing Fatty Acid Metabolism},
  journal = {Frontiers in Bioscience-Landmark},
  year = {2025},
  volume = {30},
  number = {1},
  doi = {10.31083/fbl26700}
}
Kostenlos starten →